New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 18, 2020 - The FDA approved Merz Pharmaceuticals’ Xeomin (incobotulinumtoxinA), for the treatment of chronic sialorrhea in patients 2 years of age and older.
Download PDF
Return to publications
